Clinical trial · Interventional
Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): MRI Linac contract was not renewed at our institution after Viewray went bankrupt. Therefore we cannot do adaptive treatments on this machine. No patients were enrolled.
Summary
Brief summary (as posted)
The purpose of this research is to determine whether it is feasible to treat patients with Human Papilloma Virus positive (HPV-positive) oropharyngeal tumors on a specialized treatment machine (MRIdian linear accelerator \[Linac\]), which utilizes magnetic resonance imaging (MRI) for radiation planning and delivery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharynx Cancer | Malignant Oropharyngeal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRIdian Linac | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MRIdian Linac Group
- description
- All accrued participants will be enrolled onto the MRIdian Linac Group. Participants will receive adaptive radiotherapy (ART) on the MRIdian Linac. Participants will complete the duration of their radiotherapy regimen on the MRIdian Linac for approximately 7 weeks.
- interventionNames
- Device: MRIdian Linac
Primary outcomes (2)
- measure
- Percent difference between initial reference plan and adaptive weekly RT plan
- timeFrame
- Up to 6 months
- description
- Weekly adaptive plans will be compared to the initial reference plan and compared using a percent difference equation estimating the actual values of the quantities used as dosimetric constraints for each participant between the initial reference plan and the weekly adaptive plan\[s\].
- measure
- Evaluation of deformable imaging registration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed new diagnosis of HPV-positive OPC \[i.e. Base of tongue, tonsil, soft palate, vallecula, and posterior pharyngeal wall\] * American Joint Committee on Cancer (AJCC) 8th edition Stage I-III planned for definitive chemoradiation. * Members of all races and ethnic backgrounds * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for duration of study participation. * Must be able to understand and sign an Institutional Review Board (IRB)-approved written informed consent document. Exclusion Criteria: * Prior surgery, chemotherapy, or radiation treatment for head and neck cancer * Prior history of cancer other than non-melanomatous skin cancer * Distant metastases (cM1) or (pM1) disease) * Evidence of a compromised airway * Medical contraindications to MRIs * Unable to tolerate MRIs without sedation * Pregnant patients * Breastfeeding patients * Eastern Cooperative Oncology Group (ECOG) performance status \>1
References
Publications (0)
Data not yet available